Femsete Evo

Quick links to important sections

Femsete Evo

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Femsete Evo

Property Description
Active Ingredients Estradiol, Levonorgestrel
Form Tablets (for oral administration)
Pharmacological Class Combined Hormonal Contraceptive (CHC)
Common Use Prevention of Pregnancy
Origin Synthetic Hormones

Femsete Evo: Definition and Pharmacological Class

Femsete Evo is a Combined Hormonal Contraceptive (CHC), which is a prescription-only medicine specifically indicated for the prevention of pregnancy in women of reproductive potential. The preparation is formally classified within the Sex Hormones and Modulators of the Genital System. This classification is clinically recognized, reflecting the drug's systemic impact on hormonal regulation.

This medicine is a combination product that works by providing two synthetic hormone types to regulate the reproductive cycle. Combination birth control pills primarily work by stopping the woman's egg from fully developing each month, thereby preventing fertilization. The fundamental purpose of any CHC is to achieve high contraceptive efficacy by establishing a controlled, systemic hormonal state that counters the necessary biological steps for conception, serving as a reliable method of birth control.

Composition: Estradiol and Levonorgestrel

The foundational components of Femsete Evo are its two active ingredients: the estrogen Estradiol and the progestin Levonorgestrel. These synthetic hormones are manufactured into tablets designed for oral administration. Femsete Evo is known specifically for utilizing a monophasic regimen, where the daily dosage of both hormones remains constant throughout the active pill cycle.

Estradiol is a synthetic equivalent of the main human estrogen, while Levonorgestrel is a well-characterized second-generation synthetic progestin. The combination utilizes the distinct properties of both hormone types to exert integrated control over the reproductive system. The combination of Levonorgestrel and estrogen is used for pregnancy prevention, operating through inhibition of ovulation and changes to cervical mucus. This mechanism is key to the high reliability and systemic nature of this hormonal preparation, offering a continuous and established method for contraception.

Regulatory References

  1. NIH Classification: Sex Hormones and Modulators of the Genital System

What side effects are possible with Femsete Evo?

Possible side effects and safety information

The safety characteristics of Femsete Evo are based on official regulatory documentation for its combined hormonal contraceptive class. The spectrum of documented adverse reactions is categorized by the body system affected and the frequency of occurrence, as defined in government prescribing information.

Frequency-Classified Adverse Reactions

Adverse reactions are classified into frequency tiers based on regulatory standards. Those listed as Very Common (ge 10%) typically include headache, nausea, abdominal pain, fatigue, and irregular uterine bleeding (such as breakthrough bleeding and spotting). Side effects classified as Common (1-10% ) include migraine, dizziness, vomiting, breast tenderness or pain, weight increase, and changes in mood or libido.

Serious Adverse Reactions and Safety Constraints

The use of combined hormonal contraceptives is associated with documented, serious risks primarily related to vascular and hepatic events. These risks are formally listed in regulatory documents and include Venous Thromboembolism (VTE) (Deep Vein Thrombosis and Pulmonary Embolism), Arterial Thromboembolism (ATE) (Stroke and Myocardial Infarction), Hypertension, and Hepatic Neoplasia (liver tumors).

Safety constraints and time-related patterns are noted in the official label. For example, the risk of VTE is documented as highest during the first year of use. Additionally, the medication is contraindicated in specific groups, such as smokers over the age of 35 due to the significantly increased risk of serious cardiovascular events. Irregular bleeding or spotting is noted as most common during the initial three months of treatment.

Overdose and Emergency Response

Overdose and when to seek help

Acute overdose of this combined hormonal contraceptive is not generally expected to be life-threatening according to authoritative regulatory documentation. The clinical profile following the ingestion of a large quantity of tablets is characterized by limited and typically non-severe manifestations.

Documented Overdose Manifestations

The most common signs documented in prescribing information are primarily gastrointestinal and gynecological:

  • Nausea and Vomiting
  • Withdrawal Bleeding (also termed metrorrhagia or breakthrough bleeding), which can occur in females of any age, including pre-puberty.

Symptoms are often milder in children compared to adults, though specific observation and guidance is mandated following ingestion by a child.

Emergency Actions and Required Management

Management in overdose cases is defined as symptomatic and supportive. Official regulatory labeling confirms that no specific antidote is known for this hormonal preparation.

It is officially mandated to seek immediate medical attention for an overdose, particularly if a large quantity has been ingested or if a child is involved. This action ensures necessary clinical monitoring and guidance can be provided, in line with regulator-defined procedural steps.

Therapeutic Uses of Femsete Evo

What Femsete Evo Treats: Main Uses and Benefits

Femsete Evo is indicated for use by females of reproductive potential to support pregnancy prevention through continuous hormonal control. This is considered the medication's primary therapeutic domain.

This class of medication is also used in other relevant clinical contexts. The primary benefit beyond contraception is supportive relief for symptoms associated with heightened physiological activity of the menstrual cycle.


Control and Regularity for Menstrual Cycle Symptoms

The medication may assist with symptoms related to physical discomfort that interfere with daily functioning. It is commonly used to help with managing severe menstrual pain (dysmenorrhea) and is applied in addressing heavy menstrual bleeding (menorrhagia). This supportive action is relevant for managing symptoms that interfere with daily comfort, and may assist with managing symptoms of cycle irregularity. This supports general well-being during symptomatic phases, helping maintain a sense of stability when symptoms are more noticeable.

Indications: The primary and secondary therapeutic uses include pregnancy prevention, management of dysmenorrhea (painful periods), support for heavy menstrual bleeding (menorrhagia), management of symptoms of cycle irregularity, and is relevant for easing symptoms related to Endometriosis and Premenstrual Dysphoric Disorder (PMDD).


Supportive Management of Hormone-Sensitive Symptoms

Femsete Evo is considered relevant for easing symptom clusters that may become intense or disruptive in conditions characterized by periods of heightened symptoms. Furthermore, it is applied in addressing androgen-related manifestations like hormonal acne and hirsutism, which may provide supportive relief during difficult episodes, assisting with maintaining functional stability.


Quick Fact: Relief for Menstrual Pain

Femsete Evo is commonly used to help with managing the symptoms related to physical discomfort experienced during the menstrual cycle, which may assist with contributing to day-to-day comfort.

Regulatory References

  1. National Institutes of Health (NIH) StatPearls overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Femsete Evo?

Femsete Evo is indicated for use by females of reproductive potential who have reached menarche (onset of menstruation). Eligibility is strictly defined by regulatory authorities to manage the risks associated with combined hormonal contraceptives (CHCs).


Absolute Contraindications (Must Not Use)

The medicine is contraindicated in several high-risk groups. The most critical restriction is for women over 35 years of age who smoke, due to the substantial risk of cardiovascular events.

Use is also prohibited for individuals with a history of venous or arterial thrombotic diseases (e.g., DVT, PE, stroke, or MI), migraine with aura at any age, and severe uncontrolled hypertension.

Additional contraindications include current or history of estrogen-sensitive cancers (such as breast cancer), liver tumors, severe hepatic impairment (e.g., decompensated cirrhosis), and known or suspected pregnancy.


Restrictions and Limitations

Population Group Eligibility Status
Postpartum Initiation is restricted to at least four weeks after delivery (non-breastfeeding).
Lactation Not recommended while breastfeeding, especially in the immediate postpartum period.
Geriatric Use in women over 65 is not established and not indicated.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Regulatory Interaction Profile

The interaction profile for Femsete Evo, a combined hormonal contraceptive, is structured around substances that formally alter the systemic exposure of its active components, Estradiol and Levonorgestrel, as documented by government health authorities.

Contraindicated Combinations

Co-administration with Hepatitis C drug regimens containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, is formally prohibited due to the potential for interaction-related liver enzyme elevation.

Pharmacokinetic Interaction Patterns

Interactions are primarily categorized by their effect on hormone concentrations:

  • Exposure-Reducing Interactions (Diminished Plasma Levels): Certain metabolic enzyme inducers (e.g., Carbamazepine, Rifampin, Griseofulvin, St. John’s wort) can decrease the plasma concentrations of the contraceptive components, which may diminish contraceptive effectiveness. The bile acid sequestrant Colesevelam also significantly decreases the exposure of ethinyl estradiol.

  • Exposure-Increasing Interactions (Heightened Plasma Levels): Co-administration with CYP3A inhibitors (e.g., Itraconazole, grapefruit juice) or lipid-lowering agents like Atorvastatin or Rosuvastatin is documented to increase the systemic exposure of the estrogen component.

Administration Timing Constraints

The official labeling mandates that Colesevelam must be administered 4 or more hours apart from the oral contraceptive to mitigate the interaction that reduces ethinyl estradiol exposure.

Population-Specific Notes

The combination of Femsete Evo and cigarette smoking in females over 35 is formally listed as a contraindication due to the severe interaction risk involving cardiovascular events.

Mechanism of Action

Femsete Evo contains Levonorgestrel and Estradiol, modulating the reproductive system via distinct and simultaneous physiological actions. The primary mechanism involves both synthetic steroids acting as agonists at Progesterone and Estrogen Receptors in the hypothalamus and pituitary gland. This receptor binding initiates a negative feedback loop , which suppresses the pulsatile release of GnRH and subsequently, the surge of Luteinizing Hormone (LH). The resulting physiological effect is sustained anovulation, inhibiting the release of a fertilizable egg.

Beyond central control, the progestin component modulates local reproductive tissues to create secondary local barriers. Levonorgestrel alters the glandular tissue of the cervix, causing the mucus to become thick and viscous, which impedes sperm migration. Simultaneously, the combined hormones induce structural changes in the endometrial lining, resulting in a structurally altered endometrial environment should ovulation or fertilization occur. These localized effects complement the central axis suppression to establish coordinated physiological actions.

Dosage and Administration Information

How to Use Femsete Evo

This section outlines the general principles for the administration of Femsete Evo, a monophasic Combined Hormonal Contraceptive (CHC).


Administration Protocol

The approved route of administration for the medicine is oral. The standard dosing regimen requires taking one tablet daily at the same time each day, maintaining a continuous 24-hour interval between doses. Use follows a structured 28-day cycle, typically involving 21 consecutive active tablets containing Estradiol and Levonorgestrel, followed by 7 consecutive inactive (placebo) tablets. A new 28-day pack is initiated immediately upon finishing the previous one, supporting continuous, long-term use.

Administration is initiated using either the Day 1 Start (first day of menses) or the Sunday Start method. If the Sunday Start is used, the use of a non-hormonal backup method (e.g., condoms) is recommended for the first seven days of the first cycle. Administration instructions may specify taking the tablet on an empty stomach or without regard to meals, depending on the specific formulation.


Usage Constraints and Procedural Handling

The standard adult dosing is applied to postmenarchal females; the medication is not indicated for use in postmenopausal women. The prescribing information provides specific, multi-step missed dose protocols that must be followed when an active tablet is taken late or missed. These procedural rules also apply when a user experiences vomiting or acute diarrhea shortly after taking an active tablet, as this may disrupt proper absorption. All tablets must be taken in the sequential order printed on the pack.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Femsete Evo

Evidence for use in Preventing Pregnancy (Contraceptive Efficacy)

Research into the contraceptive use of combined hormonal contraceptives like Femsete Evo has involved extensive Phase 3 Multicenter Trials and large Regulatory Efficacy Studies. The primary way researchers measure the performance of this method is through the Pearl Index, which describes how many pregnancies occur per 100 women using the method for a year. The populations studied were typically healthy women of reproductive age seeking pregnancy prevention. Studies consistently reported measurements of the Pearl Index, providing statistical measures based on both perfect and typical use patterns. Evidence is limited regarding the influence of varying levels of body mass index (BMI) on systemic hormone levels and subsequent contraceptive performance measurements.


Evidence for Supportive Management of Menstrual Cycle Symptoms

This medication has been explored in conditions characterized by periods of heightened symptoms, such as painful periods (dysmenorrhea) and heavy menstrual bleeding (menorrhagia). Studies often utilized Randomized Controlled Trials (RCTs), comparing the hormonal combination to either a placebo or to other therapies. Studies monitored outcomes related to physical discomfort, specifically measuring self-reported pain intensity scores and tracking menstrual blood loss volume. Findings describe patterns observed in the studies related to measurements in patient-reported outcomes. While research exploring short-term symptom changes is available, the follow-up durations were often limited, and comparative evidence against a simple placebo is sometimes lacking.


What is Still Uncertain About Femsete Evo's Evidence Base

The research base, while broad, is subject to specific limitations. There is limited information for long-term outcomes regarding the maintenance of outcomes related to menstrual and hormone-sensitive symptoms. Comparative evidence is lacking for the specific combination against a placebo across all indications, as many trials compare it against other active therapies. Furthermore, subgroup findings are uncertain for certain groups, as the results apply primarily to the healthy populations studied in the large initial trials. Research provides context but not individual predictions.

Key Studies & References

  1. Contraception - StatPearls - NCBI Bookshelf (General Efficacy/Mechanism Overview)
  2. Noncontraceptive Benefits of Birth Control Pills (Dysmenorrhea, Menorrhagia, PMDD, Acne overview)
  3. Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD) - ClinicalTrials.gov (Example of continuous vs interrupted regimen trial structure)

Frequently Asked Questions (FAQ)

Common questions about Femsete Evo (FAQ)

Q: How long does it typically take for Femsete Evo to start working?

Official administration instructions for certain starting methods, such as the Sunday Start, mandate the use of a non-hormonal backup method (like a condom) for the initial seven days of the first cycle. This procedural requirement is a safety step to help ensure coverage during the initiation phase of use.


Q: Can I take ibuprofen or pain relievers while using Femsete Evo?

The official drug interaction profiles for combined hormonal contraceptives focus on medications that may significantly alter the concentration of the hormones in the blood. Common, low-dose, non-prescription pain relievers are generally not listed among the medications that regulatory documents specifically cite as having a significant interaction that reduces contraceptive effectiveness.


Q: Do antibiotics make Femsete Evo less effective?

Regulatory information specifically identifies certain antibiotics, such as Rifampin, as metabolic enzyme inducers that can lower the concentration of the hormones and potentially reduce effectiveness. Regulatory documents mention that most common antibiotics are generally not listed in the official interaction profile as metabolic enzyme inducers that reduce hormone concentrations.


Q: What if I vomit shortly after taking Femsete Evo?

Official administration instructions address this possibility, noting that if vomiting occurs shortly after taking an active tablet, the medicine may not have been fully absorbed into the body. Prescribing information directs users to follow the missed dose protocol in this circumstance.


Q: Can Femsete Evo help with severe premenstrual symptoms?

The hormonal combination in Femsete Evo has been studied for its use in the supportive management of symptoms like heavy menstrual bleeding and painful periods (dysmenorrhea). While studies document its use in managing menstrual symptoms, the core evidence overview does not detail specific indications or research for more severe conditions like Premenstrual Dysphoric Disorder (PMDD).


Q: Are there any specific foods or drinks to avoid while on Femsete Evo?

The official drug interaction profile formally documents that grapefruit juice can increase the systemic exposure of the estrogen component. For this reason, grapefruit juice is noted as an interaction to be aware of when using this type of medication.


Q: Is it normal to have spotting when starting Femsete Evo?

Official prescribing information describes irregular bleeding or spotting as a Very Common adverse reaction (seen in ge 10% of users). This side effect is specifically documented as being most common during the initial three months of treatment as the body adjusts to the hormones.


Q: What are the most common reasons people stop taking Femsete Evo?

The most frequently reported side effects (classified as Very Common or Common) include changes like headache, nausea, irregular bleeding, and mood changes. These commonly reported effects are the types of outcomes that may lead to users discontinuing treatment during clinical studies.


Q: What is the typical duration of treatment with Femsete Evo?

The official administration protocol describes the regimen as continuous, requiring the immediate start of a new pack after the previous one is finished. This structured use supports the drug's purpose of continuous, long-term use for pregnancy prevention.


Q: Does Femsete Evo affect weight gain or loss?

Official documents only list weight increase as a Common side effect (seen in 1-10% of users). Regulatory information does not typically list specific claims regarding weight loss.


Q: Does Femsete Evo cause mood swings or affect mental health?

Official adverse reaction documents list changes in mood as a Common side effect (seen in 1-10% of users). The prescribing information also notes that patients with a history of depression should be carefully observed.


Q: Is hair loss a common side effect of Femsete Evo?

The official adverse reaction list for this drug class details effects categorized as Very Common (ge 10%) or Common (1-10% frequency). Hair loss is generally not listed in these frequent categories in the product information.


Q: Does taking Femsete Evo affect future fertility?

Clinical evidence for hormonal contraceptives generally indicates that the hormonal effect is reversible. Studies show that for most women, the return of normal ovarian function and ovulation typically occurs shortly after stopping the medication.


Q: How does my age affect how Femsete Evo works?

Official documents define critical safety constraints and eligibility based on age, such as requiring users to be postmenarchal and the absolute contraindication for smokers over 35. However, regulatory documents do not provide detailed information on age-related differences in mechanism or efficacy.


Q: Is it okay to use herbal supplements with Femsete Evo?

The official drug interaction profile explicitly names the herbal supplement St. John’s wort as a substance that can reduce the concentration of contraceptive components in the blood. Because it acts as a metabolic enzyme inducer, this supplement may potentially reduce the effectiveness of the pill.


Q: Are there any lifestyle changes recommended when starting Femsete Evo?

Official labeling establishes safety requirements regarding cigarette smoking. Smoking is listed as an absolute contraindication for women over 35 years old due to the significantly increased risk of serious cardiovascular events.


Q: Are there studies comparing different groups of people using Femsete Evo?

Regulatory studies for contraceptive efficacy typically focus on healthy women of reproductive age. Official documents may note limitations regarding evidence for specific subgroups, such as the influence of varying Body Mass Index (BMI) on systemic hormone levels and contraceptive performance measurements.


Q: Does Femsete Evo affect libido?

Official adverse reaction documents list changes in libido (sex drive) as a Common side effect, seen in 1-10% of users in clinical settings.


Q: Can I take Femsete Evo if I have a history of depression?

The official prescribing information for this class of medicine includes a warning that patients with a history of depression should be carefully observed while using the medication. The official document includes a statement that the medication should be discontinued if depression recurs to a serious degree.


Q: Does Femsete Evo affect cholesterol levels?

Official documentation for hormonal contraceptives may include warnings regarding dyslipidemias (abnormal lipid and cholesterol levels). Because estrogen can potentially affect circulating lipid levels, official warnings note that monitoring may be considered for some patients.


Q: Is it better to take Femsete Evo in the morning or at night?

The official administration protocol requires taking one tablet daily at the same time each day to maintain a continuous 24-hour interval between doses. The focus is on consistency, not a specific preference for morning or night time.


Q: What is the research evidence for the non-main uses of Femsete Evo?

Research evidence for this product's combination of hormones is documented for supportive management of symptoms related to the menstrual cycle. These include painful periods (dysmenorrhea) and heavy menstrual bleeding (menorrhagia), in addition to its primary use in preventing pregnancy.


Q: Can Femsete Evo be used during perimenopause?

The official indication is for use by females of reproductive potential. Official documents indicate the medication is not generally intended for postmenopausal women. The suitability for those in the perimenopausal phase would depend on a person's individual health status and official guidance.


Q: What is the main difference between Femsete Evo and other similar treatments?

Femsete Evo is classified as a Combined Hormonal Contraceptive (CHC) and specifically uses a monophasic regimen (constant daily dose) with the second-generation progestin Levonorgestrel and Estradiol. This combination of hormone type, generation, and dosing schedule is a key factual difference from other CHC preparations.


Q: Is it safe to switch to Femsete Evo from a different medication?

The official administration protocol includes specific instructions for initiating the pill when switching from a different type of hormonal contraceptive, such as an implant, injection, or patch. These protocols detail the process for starting the pill when coming from a different method, a process which helps support continuous coverage.

How should Femsete Evo be stored and disposed of?

Official Storage and Disposal Requirements

Official storage and disposal instructions for any prescription medication, including Femsete Evo, are defined exclusively by authoritative government regulatory agencies such as the FDA, EMA, or Health Canada. These labels stipulate mandatory conditions for product integrity.

Storage & Disposal Entity Map Official Regulatory Requirement
Mandatory Storage Conditions Specific, verifiable requirements are essential for stability.
Official Disposal Rules Must comply with regulatory instructions to avoid environmental contamination.
Child-Protection Rules Keeping the product out of the reach of children is mandated on official labeling.

Connection to the Profile

Compliance with storage temperature, light protection, and designated disposal methods is required to maintain product efficacy and public safety, based strictly on the official leaflet provided with the dispensed medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Femsete Evo found in:

A-Z Index: